In the 2018–19 season, American cellist Alisa Weilerstein, a 2011 MacArthur Fellowship winner, releases Transfigured Night on Pentatone, on which she is joined by Norway’s Trondheim Soloists for Haydn’s First and Second Cello Concertos and Schoenberg’s Verklärte Nacht. Two Scandinavian performances of the album’s repertoire with the same ensemble opened the season. In the spring she returns to Verklärte Nacht but in a chamber music version, when she tours Europe and the US with pianist Inon Barnatan, violinist Sergey Khachatryan, and percussionist Colin Currie. Also in the season she performs Shostakovich’s Second Cello Concerto with five different orchestras; tours the US playing Dvořák’s Cello Concerto with the Czech Philharmonic led by Semyon Bychkov, and plays the Schumann Concerto with the Rotterdam Philharmonic and Saint-Saëns’s First Cello Concerto, Britten’s Symphony for Cello and Orchestra, Richard Strauss’s Don Quixote, and Bloch’s Schelomo: Rhapsodie Hébraïque in cities ranging from San Diego to Vienna. Finally, she gives two performances of Matthias Pintscher’s new cello concerto, Un despertar, with the composer leading both the Danish National Symphony Orchestra and the Cincinnati Symphony Orchestra. She performs Bach’s complete cello suites in Beverly Hills, Paris, Berkeley, for Boston’s Celebrity Series, and at Hamburg’s Elbiphilharmonie.
Ms. Weilerstein’s career milestones include an emotionally-tumultuous account of Elgar’s Cello Concerto with the Berlin Philharmonic and Daniel Barenboim in Oxford, and a performance at The White House for President and Mrs. Obama. A champion of new music, she has worked on multiple projects with Osvaldo Golijov and Pintscher, and premiered works by Pascal Dusapin, Lera Auerbach, and Joseph Hallman. Ms. Weilerstein, whose honors include Lincoln Center’s 2008 Martin E. Segal Prize and the 2006 Leonard Bernstein Award, is a graduate of The Cleveland Institute of Music and Columbia University. Diagnosed with type 1 diabetes, she is a celebrity advocate for the Juvenile Diabetes Research Foundation.